Cardiovascular heart disease is a major health problem in the United States. Elevated blood cholesterol has been shown to significantly increase the risk of cardiovascular heart disease. The National Cholesterol Educational Program (NCEP) Step I diet, which restricts fat and cholesterol intakes, is usually recommended as the initial treatment to lower blood cholesterol. Soy protein has been shown to be hypocholesterolemic, particularly in hypercholesterolemic subjects. However, the hypocholesterolemic effect of soy protein in subjects with a blood total cholesterol concentration < 5.17 mmol/L is not clear. To determine whether soy protein could enhance the hypocholesterolemic effect of the NCEP Step I diet, 13 normocholesterolemic and 13 hypercholesterolemic men aged 20-50 y were enrolled in a randomized, 2-part, crossover study. Subjects were fed either an NCEP Step I soy-protein diet or an NCEP Step I animal protein diet for 5 wk. After a washout period of 10-15 wk, the subjects were fed the alternate diet for 5 wk. The hypocholesterolemic effect of soy protein was found to be independent of age, body weight, pretreatment plasma lipid concentrations, and sequence of dietary treatment. Regardless of plasma lipid status, the soy-protein diet was associated with a statistically significant decrease in the plasma concentrations of LDL cholesterol (P = 0.029) as well as the in the ratio of plasma LDL cholesterol to HDL cholesterol (P = 0.005). Our results indicate that soy protein enhances the hypocholesterolemic effect of the NCEP Step I diet in both normocholesterolemic and hypercholesterolemic men.
INTRODUCTION
Elevated plasma cholesterol has been implicated as a primary risk factor for cardiovascular heart disease. Dietary therapy such as the National Cholesterol Educational Program (NCEP) Step I diet (1) , which restricts fat and cholesterol intakes, is generally recommended for lowering plasma cholesterol before resorting to drug treatment. Soy protein has been shown to be hypocholesterolemic in animals (2) (3) (4) (5) (6) . Some studies in human subjects have shown a significant hypocholesterolemic effect of soy protein in hypercholesterolemic (HC) subjects (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Other studies, however, have shown an insignificant effect in hypercholesterolemic subjects (21) (22) (23) (24) (25) . The hypocholesterolemic effect of soy protein also has been shown to be minimal or negligible in normocholesterolemic subjects (22, 24, (26) (27) (28) (29) .
A recent meta-analysis of data from 38 clinical studies indicated that soy protein was effective in lowering plasma cholesterol concentrations only in humans with pretreatment plasma cholesterol concentrations > 6.47 mmol/L (30) . The report did not show any significant hypocholesterolemic effect in people with plasma cholesterol concentrations < 5.17 mmol/L (31), the threshold for dietary or drug treatment for the adult population. People with plasma cholesterol concentrations < 5.17 mmol/L represent the majority of the population in the United States and constitute the principal population group that would benefit significantly from nondrug treatment. In addition, the metaanalysis failed to include a metabolic ward study using liquid diets showing an insignificant hypocholesterolemic effect of soy protein in normocholesterolemic subjects (29) .
The purpose of this study was to determine whether soy protein, consumed in the form of regular meals, could enhance the hypocholesterolemic effect of an NCEP Step I diet in both normocholesterolemic and hypercholesterolemic men.
SUBJECTS AND METHODS

Subjects
Thirteen normocholesterolemic and 13 hypercholesterolemic men between 20 and 50 y of age were recruited for this randomized, 2-part, crossover study. The protocol was reviewed and Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men approved by the Institutional Review Board for Human Research at Baylor College of Medicine. All subjects were screened carefully to exclude those taking hypertensive or cholesterol-lowering medication as well as those consuming special diets or with chronic conditions, including gastrointestinal problems and diabetes. Criteria for enrollment as normocholesterolemic subjects included a fasting plasma total cholesterol concentration between 3.10 and 4.91 mmol/L, a fasting plasma total triacylglycerol concentration < 1.69 mmol/L, and a fasting plasma LDL cholesterol (LDL-C) concentration < 3.49 mmol/L. Criteria for enrollment as hypercholesterolemic subjects included a fasting plasma total cholesterol concentration > 6.21 mmol/L, a fasting plasma total triacylglycerol concentration < 5.65 mmol/L, and a fasting plasma LDL-C > 4.53 mmol/L. The minimal fasting plasma HDL cholesterol (HDL-C) concentration allowed for both groups was 0.91 mmol/L. Fulfillment of these criteria was based on data from 2 fasting plasma lipid profiles taken within 1 wk of one another.
Experimental diets
All subjects completed a 4-d (including 1 weekend day) food diary at home. The diaries were reviewed with a dietitian to verify accuracy and determine the subjects' eating habits, food preferences, and energy intake. Two experimental diets were used: a soy-protein diet and an animal protein diet. Each diet conformed to the NCEP Step I diet for lowering plasma cholesterol concentrations in humans. The basic design of each diet consisted of 7 daily menus, including breakfast, lunch, dinner, and snacks. The soy products were provided by Protein Technologies International (Checkerboard Square, St Louis) using SUPRO isolated soy protein. The ingredients for the animal protein diet were purchased locally. Both diets provided the subjects' usual energy intake to maintain body weight. The energy distribution of both diets was designed to be 20% protein, 30% fat, and 50% carbohydrate. Soy or animal protein comprised ≥ 75% of the total protein content of each diet. Both diets were formulated to provide similar fatty acid intakes, a cholesterol intake of 300 mg/d, and a fiber intake of 25 g/d. Soy protein was incorporated into the diet with soy products in the form of soy beverages as well as ground meat and block meat substitutes. All foods were prepared in the metabolic kitchen of the Children's Nutrition Research Center and were prepackaged for minimal preparation at home.
Randomized, 2-part, crossover study design
In the first 5-wk period, 6 normocholesterolemic and 7 hypercholesterolemic men were fed the soy-protein diet and 7 normocholesterolemic and 6 hypercholesterolemic men were fed the animal protein diet. At the end of the dietary treatment period, the subjects resumed their usual diets for 10-15 wk and were then placed on the alternate diet for a second 5-wk period. Weekly overnight fasting blood samples were collected during each dietary period.
Statistics
Analysis of covariance (ANCOVA) with repeated measures (BMDP 2V; BMDP Statistical Software, Inc, Los Angeles) was used to determine the effect of diet, age, body weight, pretreatment lipid status (normocholesterolemic versus hypercholesterolemic), sequence of dietary treatment, and interactions among these factors on plasma lipid concentrations.
RESULTS
Age, physical characteristics, and lipid profiles of the subjects are summarized in Table 1 . The hypercholesterolemic subjects were Ϸ6 y older than the normocholesterolemic subjects. Body weight and height were similar between the 2 groups. The fasting plasma lipid profiles of the normocholesterolemic and hypercholesterolemic subjects were consistent with the criteria for participation in the study. Both groups of men had normal plasma glucose concentrations. On average, the changes in body weight between the 2 dietary treatment periods (Ϫ0.7 ± 3.4 kg) for both groups were insignificant (P = 0.29). However, significant changes in body weights were observed in 2 hypercholesterolemic men (+3.6 kg and Ϫ10.4 kg) and 2 normocholesterolemic men (Ϫ6.2 kg and Ϫ9.4 kg) between the 2 dietary treatment periods. Therefore, body weight was included as a covariate in the statistical analysis.
Lipid profiles before and after 5 wk of each dietary treatment are summarized in Table 2 . There were no significant differences either between the 2 normocholesterolemic groups or the 2 hypercholesterolemic groups at the beginning of each dietary treatment (0 wk) with respect to the plasma concentrations of total cholesterol, total triacylglycerol, LDL-C, HDL-C, apolipoprotein B-100, and apolipoprotein A, as well as the ratio of LDL-C to HDL-C. The results indicated that the washout period was sufficient and also that no major changes in habitual diets had occurred during the washout period. ANCOVA with repeated measures with controls for age, body weight, and sequence of dietary treatment indicated that the plasma concentrations of LDL-C and the ratio of LDL-C to HDL-C in both normocholesterolemic and hypercholesterolemic men were significantly lower when they consumed the soy-protein diet than when they consumed the animal protein diet. As shown in Table 2 , LDL-C was Ϸ6% lower with the soy diet (P = 0.029) and the ratio of LDL-C to HDL-C was Ϸ11% lower with the soy diet (P = 0.005). The statistical analysis also showed no significant interactions between pretreatment lipid status and diet with respect to these blood lipid outcomes (P > 0.206), between group and sequence of dietary treatment (P > 0.387), and between diet and sequence of dietary treatment (P > 0.733). 
2 Significantly different from normocholesterolemic subjects, P < 0.01 (t test).
DISCUSSION
Although the hypocholesterolemic effect of soy protein has been shown repeatedly in animals (2-6, 32-39), results have been conflicting in human studies. Some studies have reported a hypocholesterolemic effect with soy (7-20, 40-44), whereas other studies have failed to find a hypocholesterolemic effect (21) (22) (23) (24) (25) (26) (27) (28) (29) 45) . In most of the studies that reported positive results, soy protein was more effective in hypercholesterolemic subjects than in normocholesterolemic subjects. However, other studies have shown an insignificant effect in hypercholesterolemic subjects (21) (22) (23) (24) (25) .
Inconsistent results can be attributed to variations in study design. For example, various soy products such as soy flour, soyprotein concentrate, textured soy protein, isolated soy protein, and soymilk have been used, resulting in ingestion of different quantities of soy protein by the test subjects. In some studies, the effect of soy protein could not be distinguished from the hypocholesterolemic effect of the simultaneous reduction in fat and cholesterol intakes associated with the dietary treatment. In 3 studies (14, 29, 42) , liquid-formula diets were used. One of these (13) reported a positive hypocholesterolemic effect of soy in 22 patients with hyperlipoproteinemia. However, cholesterol intake was not controlled and was drastically lower during the soy-protein diet period. In another study (42) , a hypocholesterolemic effect of soy protein was seen in 11 normocholesterolemic subjects with a cholesterol intake of 500 mg/d, but no effect was seen when the cholesterol intake was < 100 mg/d. In another study (29) , no effect of dietary protein was observed in 4 hypertriglyceridemic patients and 10 normotriglyceridemic patients consuming a liquid diet containing 15% soy protein or 15% casein.
Both diets used in the study reported here were designed to conform with the NCEP Step I diet (1) for lowering plasma cholesterol concentrations. Fat intake was ≤ 30% of total dietary energy, and cholesterol intake was limited to 300 mg/d. Soy protein derived from products made of isolated soybean protein constituted ≥ 75% of the total protein content of the soy-protein diet, whereas animal protein constituted ≥ 75% of the total protein in the other diet. On average, soy protein consumption by our subjects was Ϸ50 g/d with the soy diet. To eliminate any possible effect of fatty acids and fiber on plasma cholesterol concentrations or cholesterol metabolism, all diets had similar amounts of saturated (27 g/d), monounsaturated (30 g/d), and polyunsaturated (20 g/d) fatty acids. The fiber content of both diets also was similar (25 g/d).
To promote compliance, all subjects were encouraged to contact the dietitian or study coordinator immediately if they objected to the flavor of any dietary component so that appropriate substitutes could be provided. The subjects also were reminded throughout the study to consume all food provided to them to minimize changes in body weight. The randomized, 2-part, crossover study was completed without a single dropout.
Other factors that might affect the hypocholesterolemic effect of soy include an inadequate washout period between dietary treatments, noncompliance with the dietary treatments, and insufficient soy protein in the diet. In our study, the subjects resumed their habitual diets for 10-15 wk before they started the alternate dietary treatment. Results shown in Table 2 clearly demonstrate that, on average, our subjects had returned to their basal plasma lipid status before the second 5-wk diet period. Compliance with the dietary treatments was excellent in our pro- gram because the foods were prepackaged so that minimal preparation would be required at home. Knowing the subjects' eating habits and food preferences before the study helped our dietitians and kitchen staff to provide food products that were acceptable to the subjects. The flexibility to replace foods that were not well tolerated by the subjects also encouraged compliance. In other studies, the amount of soy protein ingested varied between 17 and 124 g/d; lower soy protein intakes might be insufficient to alter plasma cholesterol concentrations.
CHOLESTEROL-LOWERING EFFECT OF SOY 1387S
A hypocholesterolemic effect was reported in 11 normocholesterolemic subjects consuming a liquid soy diet (42) when cholesterol intake was 500 mg/d. No effect was observed when the cholesterol intake was ≤ 100 mg/d (27) . In a metabolic-ward study of 4 hypertriglyceridemic patients and 10 normotriglyceridemic patients consuming liquid diets (29), no effect was observed when cholesterol intakes ranged from 150 to 256 mg/d. In that study, the subjects were fed either a casein or liquid soyprotein diet for 1 mo and were then switched to the alternate diet for another month, with no washout period between the 2 dietary treatments. In 10 subjects, the cholesterol intake was lower when they were on the soy diet than when they were on the casein diet. In 2 subjects, the cholesterol intake was higher with the soy diet than with the casein diet. In 1 subject, the cholesterol intake was the same with both diets. Therefore, it is possible that the hypocholesterolemic effect of soy was masked by the insufficient number of subjects in the study, particularly in the hypertriglyceridemic group; by the variation in cholesterol intakes between the 2 diets; or by a carryover effect, because there was no washout between the 2 dietary treatments.
The hypocholesterolemic effect of soy protein in the normocholesterolemic and hypercholesterolemic men in the present study was much lower than that reported in patients with cardiovascular heart disease treated with drugs such as simvastatin (46) . Because people with plasma cholesterol concentrations < 5.17 mmol/L represent the majority of the US population, the use of drugs such as simvastatin to treat people with blood cholesterol concentrations < 6.47 mmol/L and without cardiovascular heart disease is debatable. Therefore, dietary therapy is the first treatment recommended by the American Heart Association to be used against diet-induced hypercholesterolemia. Although the amount of soy protein required to lower LDL-C concentrations or the ratios of LDL-C to HDL-C in our study subjects was 50 g/d, our results indicate that dietary soy protein enhances the hypocholesterolemic effect of an NCEP Step 1 diet. More importantly, the hypocholesterolemic effect was found to be similar between the normocholesterolemic and hypercholesterolemic men after age, body weight, and sequence of dietary treatment were controlled for. These data, along with other data in the literature, should encourage the American public to include soy protein in their diets and to modify their eating habits to guard against coronary heart disease related to diet-induced hypercholesterolemia.
